Several cases of leukemia have occured among γ-chain-deficient patients who received gene therapy. In these cases, the retroviral vector had integrated close to the LMO2 proto-oncogene in the leukemia clone, leading to abberant transcription and expression of LMO2. Because of this setback, clinical trials of gene therapy for SCID are being carefully evaluated, and more experience is required before the definitive role of gene therapy in SCID is established.
No comments:
Post a Comment